Enzyme experiment extended survival in pancreatic cancer

Share this article:

Adding an enzyme to the standard chemotherapeutic regimen for pancreatic cancer nearly doubled overall survival time in a mouse model.

Pancreatic ductal adenocarcinomas are highly resistant to chemotherapy, due in part to a unique biologic barrier the tumor builds around itself. In the current study, the research team identified hyaluronan, or hyaluronic acid (HA), as the primary matrix component of these barriers and showed that systemic administration of an enzyme known as PEGPH20 could degrade HA in the tumor barrier.

Working with a genetically engineered mouse model of pancreatic ductal adenocarcinoma, the investigators combined the PEGPH20 enzyme with gemcitabine, the current standard chemotherapeutic agent employed to combat such tumors. Use of the enzyme set off a chain of biologic events that ultimately broke down the barrier and allowed high concentrations of chemotherapy to reach the tumor and spread throughout the diseased tissue (Cancer Cell. 2012;21[3]:418-429). The result was a 70% increase in overall survival after the start of treatment, from 55 days to 92 days.

Early clinical trials in humans are under way in the United States and in Russia; visit http://clinicaltrials.gov/show/NCT01453153 for eligibility and enrollment information.

Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Landmark Medicare law had little impact on reducing chemotherapy cost

Legislation passed in 2003 intended to slow the spiraling costs of drugs paid for by the federal government to treat Medicare patients has not proved to be a success.

Follow-up colonoscopies too frequent and overused by endoscopists

A retrospective study has uncovered an overuse of colonoscopies for colorectal cancer screening and surveillance.

Current therapy for hypothyroidism endorsed by new guidelines

A recent review has found insufficient consistent data exist to recommend a change in use of levothyroxine as the only drug needed to treat hypothyroidism.